Status:

Grey - after consultant/specialist initiation, Red, Green

Decision Date:

None

Comments

GREEN: 

• Nasal spray 64mcg - 2nd line option.  See referral guide for Allergic Rhinitis in adults and adolescents over 12 years of age and Rhinosinusitis (chronic) management.  (Decision date - March 2016).
  
• Enema- 2mg foam enema, 2mg/100ml enema.
• Inhaler - Easyhaler, (Breath actuated DPI) for adults and children (>6 years of age) in asthma.  (Decision date - March 2017).

 GREY after consultant/specialist initiation: 

•  MR oral preparation.  After consultant gastroenterologist and colorectal surgeon initiation.  Long term maintenance with low dose (off-label) may be required in exceptional circumstances e.g., autoimmune hepatitis, microscopic colitis.  (Decision date - January 2017).

RED:

•  NICE TA708: Orodispersible tablet (Jorveza) for inducing remission of eosinophilic oesophagitis.  Indicated for the treatment of eosinophilic oesophagitis in adults for 6 weeks. Continue for up to 12 weeks if inadequate response.  (Decision date - April 2019).
• NICE TA937: for treating primary IgA nephropathy (Kinpeygo). (Decision date - January 2024)

Inhaled budesonide should no longer be considered as a treatment for individuals with COVID-19 infection other than within the context of a clinical trial.  People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19.  See NICE NG191 Covid-19 rapid guideline: managing COVID-19 (updated Dec 2021).

search again